A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic dbdb Mice and Type 2 Diabetes Patients
Joint Authors
Terasaki, Michishige
Hiromura, Munenori
Mori, Yusaku
Kohashi, Kyoko
Kushima, Hideki
Koshibu, Masakazu
Saito, Tomomi
Yashima, Hironori
Hirano, Tsutomu
Watanabe, Takuya
Source
International Journal of Endocrinology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-09
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Dipeptidyl peptidase-4 (DPP-4) inhibitors could have antiatherosclerotic action, in addition to antihyperglycemic roles.
Because macrophage foam cells are key components of atherosclerosis, we investigated the effect of the DPP-4 inhibitor teneligliptin on foam cell formation and its related gene expression levels in macrophages extracted from diabetic db/db (C57BLKS/J Iar -+Leprdb/+Leprdb) mice and type 2 diabetes (T2D) patients ex vivo.
We incubated mouse peritoneal macrophages and human monocyte-derived macrophages differentiated by 7-day culture with oxidized low-density lipoprotein in the presence/absence of teneligliptin (10 nmol/L) for 18 hours.
We observed remarkable suppression of foam cell formation by teneligliptin treatment ex vivo in macrophages isolated from diabetic db/db mice (32%) and T2D patients (38%); this effect was accompanied by a reduction of CD36 (db/db mice, 43%; T2D patients, 46%) and acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) gene expression levels (db/db mice, 47%; T2D patients, 45%).
Molecular mechanisms underlying this effect are associated with downregulation of CD36 and ACAT-1 by teneligliptin.
The suppressive effect of a DPP-4 inhibitor on foam cell formation in T2D is conserved across species and is worth studying to elucidate its potential as an intervention for antiatherogenesis in T2D patients.
American Psychological Association (APA)
Terasaki, Michishige& Hiromura, Munenori& Mori, Yusaku& Kohashi, Kyoko& Kushima, Hideki& Koshibu, Masakazu…[et al.]. 2018. A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic dbdb Mice and Type 2 Diabetes Patients. International Journal of Endocrinology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1172171
Modern Language Association (MLA)
Terasaki, Michishige…[et al.]. A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic dbdb Mice and Type 2 Diabetes Patients. International Journal of Endocrinology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1172171
American Medical Association (AMA)
Terasaki, Michishige& Hiromura, Munenori& Mori, Yusaku& Kohashi, Kyoko& Kushima, Hideki& Koshibu, Masakazu…[et al.]. A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic dbdb Mice and Type 2 Diabetes Patients. International Journal of Endocrinology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1172171
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1172171